Waters Corporation
Waters Corporation Completes Spin-off and Combination with BD’s Biosciences and Diagnostic Solutions Businesses
Summary
On February 9, 2026, Waters Corporation (NYSE: WAT) completed the spin-off and combination of Becton, Dickinson and Company's (NYSE: BDX) Biosciences and Diagnostic Solutions businesses. This transaction established Waters as a global life sciences and diagnostics leader with four new divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. As part of the transaction, Claire M. Fraser, Ph.D., was appointed to the Waters Board of Directors, effective February 9, 2026. The new entity is focused on high-volume testing in regulated applications and expanding into high-growth adjacent markets.
Profitelligence Alerts
Get alerts for WAT
Be first to know when Waters Corporation files with the SEC.
Filing Categories
Advertisement
About Waters Corporation
Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.
Official SEC Documents
Advertisement